Phase 1b Study of IC14 in Arrhythmogenic Cardiomyopathy
Latest Information Update: 22 Sep 2025
At a glance
- Drugs Atibuclimab (Primary)
- Indications Arrhythmogenic right ventricular dysplasia
- Focus Adverse reactions; Proof of concept
- Sponsors Implicit Bioscience
Most Recent Events
- 10 Sep 2025 Status changed from active, no longer recruiting to suspended, as study paused but may start again in the future.
- 11 May 2025 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2024 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.